TRILUMINATE Pivotal Trial

Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal

The primary objective of this trial is to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (TriClip device) to Control (Medical Therapy).

Study Overview

• Status: Active, not recruiting
• Conditions: Tricuspid Regurgitation
• Intervention / Treatment: Device: TriClipTM Device

• Study Type: Interventional
• Enrollment (Actual): 572
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Natalie Richardson; Phone Number: 651-756-3842; Email: natalie.richardson@abbott.com

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V6Z 2E8
      • St. Paul's Hospital
  • Ontario
    • Hamilton, Ontario, Canada, L8L 2X2
      • Hamilton Health Science Centre
    • Ottawa, Ontario, Canada, K1Y 4W7
      • Ottawa Heart Institute
    • Toronto, Ontario, Canada, M5B 1W8
      • St. Michael's Hospital
    • Toronto, Ontario, Canada, M5N 3M5
      • Sunnybrook Health Science Centre
  • Quebec
    • Montréal, Quebec, Canada, H1T 1C8
      • Institut de Cardiologie de Montreal (Montreal Heart Inst.)
    • Montréal, Quebec, Canada, H4A 3J1
      • The Royal Victoria
• Germany
  • Bavaria
    • München, Bavaria, Germany, 81377
      • München Grosshadern
  • North Rhine-Westphalia
    • Bonn, North Rhine-Westphalia, Germany, 53105
      • Universitätsklinikum Bonn AdöR
  • Rhineland-Palatinate
    • Mainz, Rhineland-Palatinate, Germany, 55131
      • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
  • Saxony
    • Leipzig, Saxony, Germany, 04289
      • Herzzentrum Leipzig GmbH
• Italy
  • Lombard
    • Milano, Lombard, Italy, 20132
      • Ospedale San Raffaele - Cardiac
• Spain
  • Catalonia
    • Barcelona, Catalonia, Spain, 08036
      • Hospital Clinic I Provincial de Barcelona
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35249
      • University Hospital - University of Alabama at Birmingham
  • Arizona
    • Phoenix, Arizona, United States, 85013
      • St. Joseph's Hospital & Medical Center
    • Phoenix, Arizona, United States, 85016
      • Arizona Cardiovascular Research Center
    • Phoenix, Arizona, United States, 85018
      • Phoenix Cardiovascular Research Group
    • Scottsdale, Arizona, United States, 85260
      • Scottsdale Healthcare Shea
    • Tucson, Arizona, United States, 85712
      • Tucson Medical Center
  • California
    • La Jolla, California, United States, 92037
      • Scripps Green Hospital
    • Los Angeles, California, United States, 90048
      • Cedars-Sinai Medical Center
    • Mountain View, California, United States, 94040
      • El Camino Hospital
    • Orange, California, United States, 92868
      • Providence Medical Foundation (St. Joseph Hospital)
    • Sacramento, California, United States, 95817
      • University of California - Davis Medical Center
    • Sacramento, California, United States, 95816
      • Sutter Medical Center, Sacramento
    • San Francisco, California, United States, 94109
      • California Pacific Medical Center
    • Thousand Oaks, California, United States, 91360
      • Los Robles Regional Medical Center
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Hospital
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Yale New Haven
  • Florida
    • Atlantis, Florida, United States, 33462
      • JFK Medical Center
    • Bradenton, Florida, United States, 34208
      • Manatee Memorial Hospital
    • Clearwater, Florida, United States, 33756
      • Morton Plant Valve Clinic
    • Delray Beach, Florida, United States, 33484
      • Delray Medical Center
    • Miami, Florida, United States, 33176
      • Baptist Hospital of Miami
    • Palm Beach Gardens, Florida, United States, 33410
      • Palm Beach Garden Medical Center
    • Tallahassee, Florida, United States, 32308
      • Tallahassee Research Institute
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Piedmont Heart Institute
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
    • Evanston, Illinois, United States, 60201
      • NorthShore University HealthSystem
  • Indiana
    • Indianapolis, Indiana, United States, 46240
      • St. Vincent Hospital
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • Kansas University Medical Center
    • Wichita, Kansas, United States, 67226
      • Cardiovascular Research Institute of Kansas
  • Louisiana
    • Houma, Louisiana, United States, 70361
      • Cardiovascular Institute of the South
  • Maryland
    • Hyattsville, Maryland, United States, 20782
      • MedStar Health Research Institute
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Beth Israel Deaconess Medical Center
    • Boston, Massachusetts, United States, 02115
      • Brigham and Women's Hospital
  • Michigan
    • Ann Arbor, Michigan, United States, 48104
      • University of Michigan
  • Minnesota
    • Minneapolis, Minnesota, United States, 55407
      • Abbott Northwestern Hospital
  • New York
    • Albany, New York, United States, 12208
      • Albany Medical Center
    • Bronx, New York, United States, 10467
      • Montefiore Medical Center - Moses Division
    • Buffalo, New York, United States, 14203
      • Buffalo General Hospital
    • Manhasset, New York, United States, 11030
      • North Shore University Hospital
    • New York, New York, United States, 10029
      • Mount Sinai Hospital
    • New York, New York, United States, 10032
      • New York-Presbyterian/Columbia University Medical Center
  • North Carolina
    • Charlotte, North Carolina, United States, 28203
      • Carolinas Medical Center
    • Charlotte, North Carolina, United States, 28204
      • Novant Health Heart and Vascular Research Institute
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • Christ Hospital
    • Cleveland, Ohio, United States, 44195
      • The Cleveland Clinic Foundation
    • Columbus, Ohio, United States, 43214
      • Ohio Health Research Institute
  • Oregon
    • Portland, Oregon, United States, 97225
      • Providence Heart and Vascular Institute
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Hospital of the University of Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15212
      • Allegheny General Hospital
    • Pittsburgh, Pennsylvania, United States, 15213
      • University of Pittsburgh Medical Center
  • Tennessee
    • Nashville, Tennessee, United States, 37205
      • St. Thomas Hospital
    • Nashville, Tennessee, United States, 37203
      • Centennial Heart Cardiovascular Consultants
  • Texas
    • Austin, Texas, United States, 78756
      • Austin Heart
    • Dallas, Texas, United States, 75226
      • Baylor Scott and White Heart and Vascular Hospital
    • Houston, Texas, United States, 77030
      • The Methodist Hospital
    • San Antonio, Texas, United States, 78229
      • Methodist Hospital of San Antonio
  • Utah
    • Murray, Utah, United States, 84157
      • Intermountain Medical Center
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • University of Virginia Medical Center
    • Falls Church, Virginia, United States, 22042
      • Inova Fairfax Hospital
    • Norfolk, Virginia, United States, 23507
      • Sentara Norfolk General Hospital
  • Washington
    • Seattle, Washington, United States, 98195
      • University of Washington Medical Center
    • Seattle, Washington, United States, 98107
      • Swedish Medical Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53215
      • Aurora Medical Group

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• In the judgment of the site local heart team, subject has been adequately treated per applicable standards (including medical management) and stable for at least 30 days as follows:

  • Optimized medical therapy for treatment of TR (e.g. diuretics).
  • Medical and/or device therapy, for mitral regurgitation, atrial fibrillation, coronary artery disease and heart failure.
  • The Eligibility Committee will confirm that the subject has been adequately treated medically.
• Subject is symptomatic with Severe TR despite being optimally treated as described above. TR severity is determined by the assessment of a qualifying TTE and confirmed by the ECL. The ECL will also request a TEE to confirm TR etiology. Note: If any cardiac procedure(s) occur after eligibility was determined, TR severity will need to be re-assessed 30 days after the cardiac procedure(s).
• The cardiac surgeon of the site local heart team concur that the patient is at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery.
• New York Heart Association (NYHA) Functional Class II, III or ambulatory class IV
• In the judgment of the TriClip(TM) implanting Investigator, femoral vein access is determined to be feasible and can accommodate a 25 Fr catheter.
• Age ≥18 years at time of consent.
• Subject must provide written informed consent prior to any trial related procedure.

Exclusion Criteria:

• Systolic pulmonary artery pressure (sPAP) > 70 mmHg or fixed pre-capillary pulmonary hypertension as assessed by right heart catheterization (RHC)
• Severe uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 180 mmHg and/or Diastolic Blood Pressure (DBP) ≥ 110 mm Hg
• Any prior tricuspid valve procedure that would interfere with placement of the TriClip(TM) device
• Indication for left-sided (e.g. severe aortic stenosis, severe mitral regurgitation) or pulmonary valve correction prior 60 days. Note: Patients with concomitant Mitral and tricuspid valve disease will have the option of getting their MR treated, and wait 60 days prior to being reassessed for the trial.
• Pacemaker or ICD leads that would prevent appropriate placement of the TriClip(TM) clip.
• Tricuspid valve stenosis - Defined as a tricuspid valve orifice of ≤ 1.0 cm2 and/or mean gradient ≥5 mmHg as measured by the ECL
• Left Ventricular Ejection Fraction (LVEF) ≤20%

• Tricuspid valve leaflet anatomy which may preclude clip implantation, proper clip positioning on the leaflets or sufficient reduction in TR. This may include:

  • Evidence of calcification in the grasping area
  • Presence of a severe coaptation defect (> 2cm) of the tricuspid leaflets
  • Severe leaflet defect(s) preventing proper device placement
  • Ebstein Anomaly - Identified by having a normal annulus position while the valve leaflets are attached to the walls and septum of the right ventricle.
• Tricuspid valve anatomy not evaluable by TTE and TEE
• Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e. noncompliant, perforated).
• MI or known unstable angina within prior 30 days
• Percutaneous coronary intervention within prior 30 days
• Hemodynamic instability defined as systolic pressure < 90 mmHg with or without afterload reduction, cardiogenic shock or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device.
• Cerebrovascular Accident (CVA) within prior 90 days
• Chronic dialysis
• Bleeding disorders or hypercoagulable state
• Active peptic ulcer or active gastrointestinal (GI) bleeding

• Contraindication, allergy or hypersensitivity to dual antiplatelet and anticoagulant therapy.

  • Note: Contraindication to either antiplatelet or anticoagulant therapy (individually not both therapies) is not an exclusion criterion.
• Ongoing infection requiring current antibiotic therapy (if temporary illness, patients may enroll 30 days after discontinuation of antibiotics with no active infection).
• Known allergy or hypersensitivity to device materials
• Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
• Life expectancy of less than 12 months
• Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
• Subject is currently participating in another clinical investigation for valvular heart disease(s).
• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. Female subjects of child-bearing potential are required to have a negative pregnancy test done within 7 days of the baseline visit per site standard test. Female patients of childbearing potential should be instructed to use safe contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release.) It is accepted, in certain cases, to include subjects having a sterilized regular partner or subjects using a double barrier contraceptive method.
• Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Randomized - Control Group; Subjects will continue to be managed on medical therapy, per physician discretion	Device: TriClipTM Device; Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Experimental: Randomized - Device Group; Subjects will undergo TriClip implantation and will continue to be managed on medical therapy, per physician discretion	Device: TriClipTM Device; Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Experimental: Single Arm Group; Subjects will receive the TriClip device and will continue to be managed on medical therapy, per physician discretion.	Device: TriClipTM Device; Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Experimental: Continued Access Study (CAS); Subjects will undergo TriClip implantation and will continue to be managed on medical therapy, per physician discretion	Device: TriClipTM Device; Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
For Randomized Cohort: Hierarchical Composite of All-cause Death or Tricuspid Valve Surgery, Heart Failure Hospitalizations, and KCCQ Improvement	Analysis of hierarchical composite of all-cause death or tricuspid valve surgery, heart failure hospitalizations, and KCCQ improvement of at least 15 points was performed in ITT population using Finkelstein-Schoenfeld method. A win ratio was also calculated to descriptively quantify the magnitude of treatment benefits. The win ratio is calculated as the ratio of the number of wins in Device versus Control patients. The primary analysis population consisted of 175 Device patients and 175 Control patients, resulting in 30,625 Device-Control patient pairs (i.e., 175 × 175).	12 Months
For Single-Arm Cohort: Rate of Survival Through 12 Months With a Quality of Life Improvement (Assessed Using KCCQ Overall Score) of at Least 10 Points Compared to Baseline.	This outcome will be assessed as the percentage of subjects meeting the definition of the endpoint.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
For Randomized Cohort - Device Group Only: Rate of Kaplan-Meier Estimate (SE) of Freedom From Major Adverse Events (MAE) Occurring Within 30 Days Post-procedure	Freedom from major adverse events (MAE) was assessed in the Attempted Procedure population (n=172). MAEs included cardiovascular mortality, new onset renal failure, endocarditis requiring surgery, and non-elective cardiovascular surgery for TriClip device-related AE post-index procedure.	30 Days
For Randomized Cohort: Change in Quality of Life as Assessed by KCCQ Score	The mean change in KCCQ score between 12 months and baseline in the Device and Control groups will be compared, while adjusting for the baseline KCCQ score. The primary analysis for this endpoint imputed a KCCQ score of 0 at 12-month visit for all subjects who experienced a heart failure related cardiovascular death or received tricuspid valve surgery prior to completing 12-month follow-up. All KCCQ scores are scaled from 0 (worst) to 100 (best possible status), where the higher score reflects a better health status.	12 months minus baseline
For Randomized Cohort: Tricuspid Regurgitation Reduction to Moderate or Less at 30-Day Visit	The percentage of subjects with tricuspid regurgitation reduced to moderate or less at 30-day visit in the Device Group will be compared with that in the Control Group. Tricuspid regurgitation severity will be graded on a 5-point scale: trace/mild, moderate, severe (severe 3), massive (severe 4), and torrential (severe 5), which has frequently been used in recent interventional tricuspid studies to categorize tricuspid regurgitation severity. This grading system follows the 2017 ASE guidelines (Zoghbi WA, Adams D, Bonow RO et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303-371.), and further stratifies the traditional "severe" category into severe (Severe 3), massive (Severe 4), and torrential (Severe 5).	30 Days
For Randomized Cohort: Change in 6 Minute Walk Test (6MWT) From Baseline to 12 Months	The primary analysis for this endpoint imputed a 6MWT distance of 0 meters for all subjects who experienced a heart failure related cardiovascular death or received tricuspid valve surgery prior to completing 12-month follow-up. Subjects who were unable to exercise due to cardiac reasons were also assigned a 6MWT distance of 0 meters at 12-month follow-up. Other subjects with missing 6MWT distance at either baseline or 12-month follow-up were excluded from the analysis.	12 Months
For Single-Arm Cohort: The Percentage of Subjects With TR Reduction by at Least 1 Grade at 30-Day Follow-up		30 days
For Single-Arm Cohort: Rate of Freedom From MAE Through 30 Days	Freedom from MAE occurring after procedure attempt (femoral vein puncture) at 30 days. Components of MAE consist of Cardiovascular Mortality, New Onset Renal Failure, Endocarditis Requiring Surgery, and Non-Elective Cardiovascular Surgery for TriClip device-related AE post-index procedure.	30 days
For Single-Arm Cohort: Change in 6 Minute Walk Test (6MWT) From Baseline to 12 Months	This analysis imputed a 6MWT distance of 0 meters for all subjects who were unable to exercise due to cardiac reasons. However, there were no subjects unable to exercise due to cardiac reasons and therefore no imputation was performed. Subjects with missing 6MWT distance at either baseline or 12-month follow-up were excluded from the analysis.	12 months
Recurrent HF Hospitalizations at 24 Months	H0: HR(24M)>1; H1: HR(24M)≤1	24 months
Freedom From All-cause Mortality, Tricuspid Valve Surgery, and Tricuspid Valve Intervention at 24 Months	H0: Survival curves of the two groups through 24 months are the same. H1: Survival curves of the two groups through 24 months are different.	24 months

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Study Director: Erin Spinner, PhD, Abbott Structural Heart; Principal Investigator: David Adams, MD, Icahn School of Medicine at Mount Sinai; Principal Investigator: Paul Sorajja, MD, Allina Health System

Study record dates

Study Major Dates

• Study Start (Actual): August 21, 2019
• Primary Completion (Actual): November 18, 2022
• Study Completion (Estimated): April 1, 2029

Study Registration Dates

• First Submitted: April 3, 2019
• First Submitted That Met QC Criteria: April 3, 2019
• First Posted (Actual): April 5, 2019

Study Record Updates

• Last Update Posted (Actual): April 8, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Cardiovascular; Tricuspid; Pivotal; ABT-CIP-10249
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Valve Diseases; Tricuspid Valve Insufficiency
• Other Study ID Numbers: ABT-CIP-10249

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes